Inhaled Nitric Oxide and Neuroprotection in Premature Infants
- Conditions
- Periventricular LeukomalaciaPrematurityBronchopulmonary DysplasiaIntraventricular Hemorrhage
- Interventions
- Drug: inhaled nitric oxide
- Registration Number
- NCT00515281
- Lead Sponsor
- University of Chicago
- Brief Summary
The purpose of this study is to determine whether inhaled nitric oxide improves the neurological outcome for premature infants.
- Detailed Description
With the advances in modern neonatal intensive care medicine in the last 20 years, survival of extremely preterm infants weighing less than 1500g (\< 3 lbs, 5 oz) has risen markedly. However, with this increased survival has come a marked increase in the number of infants with serious neurodevelopmental disabilities: Premature infants with birth weights less than 1500g who survive to go home are at significant risk for serious neurodevelopmental problems: cognitive and motor delays, blindness, deafness, and cerebral palsy. In a recent randomized, placebo-controlled clinical trial, we assessed whether giving mechanically ventilated preterm infants inhaled nitric oxide gas (iNO) for 1 week after birth decreased the incidence of death and chronic lung disease. An unanticipated outcome of that study (Schreiber et. al. 2003) and a subsequent study of those infants at 2 years of age (Mestan et. al. 2005) was that premature infants treated with inhaled nitric oxide (iNO) have improved neurodevelopmental outcomes and physical growth at 2 years corrected age, compared with placebo-treated infants (Mestan et. al. 2005). INO therapy, therefore, appears to be a new treatment to protect the premature brain during development outside the womb. The overall goal of this application is understand the efficacy of iNO treatment in improving neurodevelopmental outcomes in at-risk premature infants.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 273
- Prematurity (birthweight ≤ 1500g, < 31 weeks gestation)
- Requiring respiratory support
- Admitted to the NICU at the University of Chicago
- Severe congenital anomalies
- Genetic syndromes
- Extremely sick preterm infants requiring very high ventilatory pressures (OI ≥ 20)
- Premature infants judged by the physician as nonviable
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description INO Control (Short iNO) inhaled nitric oxide INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age INO Treatment (Long iNO) inhaled nitric oxide The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age. INO Treatment (Long iNO) oxygen The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.
- Primary Outcome Measures
Name Time Method Neurodevelopment Two years Bronchopulmonary Dysplasia (BPD) or Death 36 weeks of age corrected (BPD) or before discharge (death) Need for respiratory support at 36 weeks post-menstrual age, either as positive pressure or supplemental oxygen to maintain oxygen saturations \>90%, or death before discharge
- Secondary Outcome Measures
Name Time Method Death through discharge (up to 400 days) Death before discharge
Bronchopulmonary Dysplasia 36 weeks of age corrected Need for respiratory support at 36 weeks post-menstrual age (PMA), either as positive pressure or supplemental oxygen to maintain oxygen saturations \>90%
Supplemental Oxygen Use 40 weeks PMA BPD or Death in Infants Weighing < 750g 36 weeks of age corrected (BPD) or before discharge (death) Need for respiratory support at 36 weeks post-menstrual age, either as positive pressure or supplemental oxygen to maintain oxygen saturations \>90%, or death before discharge among infants \< 750g
BPD or Death in Infants Weighing 750-999g 36 weeks of age corrected (BPD) or before discharge (death) Need for respiratory support at 36 weeks post-menstrual age, either as positive pressure or supplemental oxygen to maintain oxygen saturations \>90%, or death before discharge among infants 750-999g
BPD or Death in Black Infants 36 weeks of age corrected (BPD) or before discharge (death) Need for respiratory support at 36 weeks post-menstrual age, either as positive pressure or supplemental oxygen to maintain oxygen saturations \>90%, or death before discharge among Black infants
Trial Locations
- Locations (1)
The University of Chicago
🇺🇸Chicago, Illinois, United States